Dose-response relationship of the beta-adrenoceptor antagonist bisoprolol in patients with coronary heart disease and chronic obstructive bronchitis
- PMID: 6149938
- DOI: 10.1007/BF00544035
Dose-response relationship of the beta-adrenoceptor antagonist bisoprolol in patients with coronary heart disease and chronic obstructive bronchitis
Abstract
The effects of single, consecutively increased, oral doses of the beta-adrenoceptor antagonist bisoprolol (5, 10, 15, 20, 30 and 40 mg) on blood pressure, heart rate and bronchomotor tone were investigated in an open acute trial with 16 patients suffering from angina pectoris due to coronary heart disease and reversible chronic obstructive bronchitis. Even the lowest dose of bisoprolol (5 mg) caused a marked, long-lasting reduction in blood pressure and heart rate. After doses exceeding 20 mg, the incidence of an exaggerated pharmacodynamic effect on heart rate (beta 1-blockade) increased with dose. At doses above 30 mg, bisoprolol showed incipient impairment of bronchomotor function (beta 2-blockade) in individual patients. It is concluded that bisoprolol exhibits high beta 1-selectivity, i.e. a wide beta 1/beta 2 split, since blockade of bronchial beta 2-receptors only occurred at doses well above the therapeutically relevant dose range. The results may not be applicable to chronic treatment.
Similar articles
-
Beta 1/beta 2-splitting of bisoprolol.J Cardiovasc Pharmacol. 1986;8 Suppl 11:S65-8. J Cardiovasc Pharmacol. 1986. PMID: 2439801
-
Long-term treatment of angina pectoris with bisoprolol or atenolol in patients with chronic obstructive bronchitis: a randomized, double-blind crossover study.J Cardiovasc Pharmacol. 1990;16 Suppl 5:S36-44. J Cardiovasc Pharmacol. 1990. PMID: 11527135 Clinical Trial.
-
Summary of short- and long-term studies with bisoprolol in coronary heart disease (CHD).J Cardiovasc Pharmacol. 1986;8 Suppl 11:S160-6. doi: 10.1097/00005344-198511001-00029. J Cardiovasc Pharmacol. 1986. PMID: 2439790
-
Bisoprolol: a new beta-adrenoceptor blocking drug.Eur Heart J. 1987 Dec;8 Suppl M:121-9. doi: 10.1093/eurheartj/8.suppl_m.121. Eur Heart J. 1987. PMID: 2897295 Review.
-
Bisoprolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and angina pectoris.Drugs. 1988 Sep;36(3):256-85. doi: 10.2165/00003495-198836030-00002. Drugs. 1988. PMID: 2903820 Review.
Cited by
-
Interaction of bisoprolol with cimetidine and rifampicin.Eur J Clin Pharmacol. 1986;31(1):59-62. doi: 10.1007/BF00870987. Eur J Clin Pharmacol. 1986. PMID: 2877885
-
Antihypertensive effects of bisoprolol during once daily administration in patients with essential hypertension. A dose-ranging study with parallel groups.Eur J Clin Pharmacol. 1986;29(5):517-21. doi: 10.1007/BF00635886. Eur J Clin Pharmacol. 1986. PMID: 2869951 Clinical Trial.
-
Pharmacodynamic profile of bisoprolol, a new beta 1-selective adrenoceptor antagonist.Br J Clin Pharmacol. 1986 Sep;22(3):293-300. doi: 10.1111/j.1365-2125.1986.tb02890.x. Br J Clin Pharmacol. 1986. PMID: 2876722 Free PMC article. Clinical Trial.
-
Efficacy and toxicity of antihypertensive pharmacotherapy relative to effective dose 50.Br J Clin Pharmacol. 2019 Oct;85(10):2218-2227. doi: 10.1111/bcp.14033. Epub 2019 Aug 19. Br J Clin Pharmacol. 2019. PMID: 31219198 Free PMC article. Review.
-
Formulary considerations in selection of beta-blockers.Pharmacoeconomics. 1993 Aug;4(2):104-21. doi: 10.2165/00019053-199304020-00005. Pharmacoeconomics. 1993. PMID: 10150154 Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical